Prevention of cardiovascular events in diabetes.
Sigal
Ronald
R
Clinical Epidemiology Program, Ottawa Hospital, Ottawa, Canada.
Malcolm
Janine
J
Arnaout
Amel
A
D000800:Angioplasty, Balloon; D000959:Antihypertensive Agents / Q000627:therapeutic use; D001241:Aspirin / Q000627:therapeutic use; D001629:Bezafibrate / Q000627:therapeutic use; D002318:Cardiovascular Diseases / Q000517:prevention & control*; D000077144:Clopidogrel; D003925:Diabetic Angiopathies / Q000517:prevention & control*; D015248:Gemfibrozil / Q000627:therapeutic use; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D006943:Hyperglycemia / Q000517:prevention & control; D006949:Hyperlipidemias / Q000517:prevention & control; D006973:Hypertension / Q000517:prevention & control; D000960:Hypolipidemic Agents / Q000627:therapeutic use; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors; D016540:Smoking Cessation; D013988:Ticlopidine / Q000031:analogs & derivatives / Q000627:therapeutic use
D000959:Antihypertensive Agents; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000960:Hypolipidemic Agents; D010975:Platelet Aggregation Inhibitors; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D000077144:Clopidogrel; D013988:Ticlopidine; D015248:Gemfibrozil; D001241:Aspirin; D001629:Bezafibrate